Home › Companies › PYPD

PolyPid

Market cap $138M 21.1M shares (vendor count, Nov 18, 2026) × $6.54 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-02-25

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. D-PLEX₁₀₀ filing2H 2026D-PLEX₁₀₀ filing, 2H 2026, notable
  2. D-PLEX₁₀₀ PDUFA dateNov 28, 2026D-PLEX₁₀₀ PDUFA date, Nov 28, 2026, thesis-defining
  3. D-PLEX₁₀₀ commercial launch1Q 2027D-PLEX₁₀₀ commercial launch, 1Q 2027, routine
  4. D-PLEX₁₀₀ EU decision2H 2027D-PLEX₁₀₀ EU decision, 2H 2027, material
  5. PD01B IND filing2H 2027PD01B IND filing, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

PLEX · ImmunoGenesis

Proprietary polymer-lipid matrix controlled-release delivery platform enabling localized, prolonged drug release at the target site over days to months; applicable to small molecules, peptides, antibodies, and nucleic acid-based drugs; disease areas include surgical site infection prevention, oncology, inflammation, and pain.

Kynatrix

Kynatrix is PolyPid's long-acting, controlled-release drug delivery technology designed to deliver high-concentration therapy locally at the site of care; applied across surgical site infection prevention and diabetic foot infection treatment programs, with potential further pipeline expansion.

Targets: GLP-1 receptor

Capital (as filed)

Cash
$6.4M cash and cash equivalents · Dec 31, 2025 (20-F)
Operating cash flow
−$7.0M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$15.5M cash, runway into 2028 per the update of Nov 11, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on PolyPid, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch PolyPid Ltd. (PYPD) — Scientific Deep Dive for D-PLEX₁₀₀ and the Kynatrix Platform Science replicated and balance sheet funded through the binary, but manufacturing inspection risk and label breadth are unresolved and unpriced, while the only two informed buyers committed under $33M cash for rights the market values at four times that.
  2. Speculative buy speculative UPDATE: PolyPid (PYPD) - The Going-Concern Paragraph Is Gone Going-concern language removed, $30M Azurity cash received, runway guided into 2028, and mid-teen to mid-twenties royalty economics now disclosed in a filing, retiring the balance-sheet failure mode while the manufacturing inspection remains the key unhedgeable risk.
  3. Speculative buy speculative UPDATE: PolyPid (PYPD) - Europe Comes Home Advanz returning EU rights adds optionality without raising the burden, as European economics were never in the valuation, while the FDA manufacturing inspection remains the load-bearing unhedgeable risk before November 28.
  4. Speculative buy speculative UPDATE: PolyPid (PYPD) - The Stewardship Receipt Pooled microbiology data showing no resistance enrichment and delayed breakthrough infections modestly helps the commercial/formulary case but does not de-risk the manufacturing inspection, which remains the key variable before November 28.
  5. Speculative buy speculative UPDATE: PolyPid (PYPD) - Labeling Talks, 17 Days Out Labeling discussions underway and FDA interactions on track are constructive hints, Advanz exit resolved without cash cost, but no FDA inspection disclosed and the stock's 30% run since October means existing holders may want to trim before the decision.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)